Favipiravir Market

The Favipiravir market is expected to expand at a CAGR of 4.7% from 2025 to 2035, driven by its established role as a broad-spectrum antiviral in treating RNA virus infections. Originally developed for influenza, Favipiravir gained significant global attention during the pandemic due to its ability to inhibit viral replication. While its use for treatment has tapered off in some countries due to the emergence of newer antivirals and vaccines, ongoing research continues to explore its potential in managing emerging viral threats, including hemorrhagic fevers and future respiratory pandemics. Its oral administration and scalable synthesis make it an attractive stockpile option for national emergency preparedness programs.

Geographically, Asia-Pacific dominates the Favipiravir market, particularly in India, China, and Japan, where emergency use authorization and local production capacity allowed rapid deployment during the crisis. Japan remains a hub due to the drug’s origin and continued government interest in antiviral preparedness. In Latin America and the Middle East, Favipiravir retains relevance in outbreak response strategies, especially where access to newer antivirals is limited. North America and Europe have adopted more selective use post-pandemic, but demand may resurface depending on future virus mutation patterns or supply chain bottlenecks for other antiviral agents.

The market report is poised that ongoing repurposing research into Favipiravir’s efficacy for other RNA viruses and viral hemorrhagic fevers such as Ebola and Lassa. There’s also an emerging focus on high-purity grades to meet stringent regulatory demands, particularly for export. API manufacturers are working to optimize yield, particle size distribution, and impurity profiles, especially for governments building national stockpiles.